Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 985

1.
3.

Comparison of first refill rates among users of sertraline, paroxetine, and citalopram.

Mullins CD, Shaya FT, Meng F, Wang J, Bron MS.

Clin Ther. 2006 Feb;28(2):297-305; discussion 296.

PMID:
16678651
4.

Economic appraisal of citalopram in the management of single-episode depression.

Sclar DA, Skaer TL, Robison LM, Galin RS.

J Clin Psychopharmacol. 1999 Oct;19(5 Suppl 1):47S-54S.

PMID:
10507508
5.

Assessment of Canadian provincial expenditures in depressed patients treated with venlafaxine XR versus SSRIs: the APEX Study.

Monfared AA, Han D, Sheehy O, Bexton B, Lelorier J.

Curr Med Res Opin. 2006 Jan;22(1):83-94.

PMID:
16393434
6.

Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants.

Wu E, Greenberg P, Yang E, Yu A, Ben-Hamadi R, Erder MH.

Curr Med Res Opin. 2008 Oct;24(10):2805-13. doi: 10.1185/03007990802336780 . Epub 2008 Aug 27.

PMID:
18755054
7.
8.

Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.

Russell JM, Berndt ER, Miceli R, Colucci S, Grudzinski AN.

Am J Manag Care. 1999 May;5(5):597-606.

9.

Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders.

Panzer PE, Regan TS, Chiao E, Sarnes MW.

Am J Manag Care. 2005 Oct;11(12 Suppl):S370-9.

10.

Escitalopram in the treatment of major depressive disorder: a meta-analysis.

Kennedy SH, Andersen HF, Thase ME.

Curr Med Res Opin. 2009 Jan;25(1):161-75. doi: 10.1185/03007990802622726 .

PMID:
19210149
11.

Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans.

Polsky D, Onesirosan P, Bauer MS, Glick HA.

J Clin Psychiatry. 2002 Feb;63(2):156-64.

PMID:
11874218
12.

Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population.

Wu E, Greenberg PE, Yang E, Yu A, Erder MH.

Curr Med Res Opin. 2008 Sep;24(9):2587-95. doi: 10.1185/03007990802303525 . Epub 2008 Jul 31.

PMID:
18674407
13.

Comparing SSRI treatment costs for depression using retrospective claims data: the role of nonrandom selection and skewed data.

Berndt ER, Russell JM, Miceli R, Colucci SV, Xu Y, Grudzinski AN.

Value Health. 2000 May-Jun;3(3):208-21.

14.

Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram.

Mullins CD, Shaya FT, Meng F, Wang J, Harrison D.

Pharmacotherapy. 2005 May;25(5):660-7.

PMID:
15899727
15.

Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis.

Hylan TR, Crown WH, Meneades L, Heiligenstein JH, Melfi CA, Croghan TW, Buesching DP.

J Affect Disord. 1998 Jan;47(1-3):71-9.

PMID:
9476746
17.

Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.

Wu EQ, Yu AP, Lauzon V, Ramakrishnan K, Marynchenko M, Ben-Hamadi R, Blum S, Erder MH.

Ann Pharmacother. 2011 Apr;45(4):441-51. doi: 10.1345/aph.1P482. Epub 2011 Mar 17.

PMID:
21415162
18.

SSRI antidepressant drug use patterns in the naturalistic setting: a multivariate analysis.

Hylan TR, Crown WH, Meneades L, Heiligenstein JH, Melfi CA, Croghan TW, Buesching DP.

Med Care. 1999 Apr;37(4 Suppl Lilly):AS36-44.

PMID:
10217392
19.
20.

Supplemental Content

Support Center